9 completed, 8 unknown, 1 recruiting. 18 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 9, Unknown 8, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Somatoform Disorders: new trials by email Literature Review of Somatoform Disorders trials Research Report on Somatoform Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Adezunap, Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders Ranquilon, Placebo - Anxiety, Neurasthenia | Phase 3 | Completed | Valenta Pharm JSC | 220 | 2022-10-12 | 2023-07-27 |
| Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ) Ozone, Oxygen - Chemotherapy-induced Peripheral Neuropathy, Pain, Neuropathic | Phase 2 / Phase 3 | Recruiting | Bernardino Clavo, MD, PhD | 42 | 2020-11-30 | 2026-09-25 |
| Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles Botulinum toxin type A, 0.9% Sodium Chloride Injection - Pain, Head, Pain Syndrome | Phase 3 | Completed | Weill Medical College of Cornell University | 75 | 2018-08-31 | 2023-02-14 |
| Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors Omeprazole, psychoeducation, Flupentixol +Melitracen - Globus | Phase 3 | Completed | Mahidol University | 40 | 2017-07-07 | 2018-08-22 |
| Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis Psychotherapy (CT or ET) - Hypochondriasis, Somatoform Disorders | Phase 3 | Completed | Goethe University | 84 | 2010-06-01 | 2014-08-06 |
| Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder Escitalopram, Placebo - Anxiety Disorders, Somatoform Disorders | Phase 3 | Completed | Massachusetts General Hospital | 100 | 2005-05-01 | 2017-12-05 |
| Integrated Treatment Program for Hypochondriasis in Primary Care Settings Relaxation response training, Psychoeducational counseling - Hypochondriasis, Somatoform Disorders | Phase 3 | Completed | Brigham and Women's Hospital | 91 | 2005-05-01 | 2013-03-19 |
| Treatment of Patients With Longstanding Unexplained Health Complaints Cognitive Behavioral Therapy, Recommendation of care (letter to general practitioner [GP]) - Somatization Disorder | Phase 2 / Phase 3 | Completed | University of Aarhus | 120 | 2005-04-01 | 2011-11-16 |
| Treatment of Medically Unexplained Physical Ailments (Somatization Disorder) Cognitive Behavioral Therapy, CBT - Somatoform Disorders | Phase 3 | Completed | University of Medicine and Dentistry of New Jersey | 172 | 2001-02-01 | 2014-01-14 |
| DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms DEPENAS cognitive and behavioural techniques - Somatoform Disorders | Phase 3 | Completed | Basque Health Service | 156 | 2001-01-01 | 2008-07-15 |
Pain (9) · Agnosia (8) · Chronic Pain (8) · Marijuana Abuse (8) · Neuralgia (5) · Peripheral Nervous System Diseases (4) · Anxiety Disorders (2) · Back Pain (2) · Brain Injuries, Traumatic (2) · Diabetes Mellitus (2) · Diabetic Neuropathies (2) · Hypochondriasis (2) · Low Back Pain (2) · Medically Unexplained Symptoms (2)
Mental Disorders (18) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Neurologic Manifestations (10) · Nervous System Diseases (9) · Chemically-Induced Disorders (8) · Neurobehavioral Manifestations (8) · Perceptual Disorders (8) · Substance-Related Disorders (8) · Neuromuscular Diseases (7) · Pathologic Processes (4) · Postoperative Complications (4) · Trauma, Nervous System (4) · Wounds and Injuries (4) · Peripheral Nervous System Diseases (3)
Cognitive Behavioral Therapy (3) · Botulinum Toxins, Type A (1) · Counseling (1) · Escitalopram (1) · GB-115 (1) · Idoxuridine (1) · Implosive Therapy (1) · Omeprazole (1) · Oxygen (1) · Ozone (1) · Palliative Care (1) · Psychotherapy (1) · Sodium Chloride (1) · flupentixol, melitracen drug combination (1)
Apurano Pharmaceuticals GmbH (8) · Basque Health Service (1) · Bernardino Clavo, MD, PhD (1) · Brigham and Women's Hospital (1) · Goethe University (1) · Mahidol University (1) · Massachusetts General Hospital (1) · University of Aarhus (1) · University of Medicine and Dentistry of New Jersey (1) · Valenta Pharm JSC (1) · Weill Medical College of Cornell University (1)
Germany (9) · United States (4) · Denmark (1) · Russia (1) · Spain (1) · Thailand (1)
Arthrur J. Barsky, MD (1) · Bernardino Clavo, MD, PhD (1) · Florian Weck, PhD (1) · Gustavo M Callico, Prof, PhD (1) · Gwendolyn S Reeve, DMD (1) · Javier I Escobar, M.D. (1) · Jose M Aiarzaguena, Dr. (1) · Katharine Phillips, MD (1) · Michael A Gara, Ph.D. (1) · Michael Miloro, DMD (1) · Monthira Maneerattanaporn, MD., MS. (1) · Pedro G Serrano-Aguilar, MD, PhD (1) · Per Fink, Dr.Med.Sc. (1)
PMID 19260079, PMID 19930729, PMID 21427067, PMID 21575276, PMID 22539780, PMID 23102757, PMID 23494213, PMID 23549581, PMID 24687190, PMID 24733808, PMID 25699252, PMID 29557815, PMID 31505519, PMID 31779159, PMID 32379556, PMID 33738491, PMID 38228287
2019 (1), R01MH040487 (1), R01MH060265 (1), R01MH072854 (1)